advertisement
Khouri AS 25
Showing records 1 to 25 | Display all abstracts from Khouri AS122819 Are Alpha-2 Adrenergic Agonists Being Used in Infants?
Aftab OM
Journal of Ocular Pharmacology and Therapeutics 2024; 0:
120010 Adjunctive use of netarsudil 0.02% in the treatment of refractory glaucoma: a one year analysis
Zhou B
International Ophthalmology 2024; 44: 335
119249 Pupillary Peaking & Presence of Dysphotopsias Following Glaucoma Tube Shunt Surgery
Gonzalez Martinez OG
Seminars in Ophthalmology 2024; 0: 1-6
121077 Uveal Effusion Syndrome Temporally Associated with Primary COVID-19 Infection
Patel NR
Seminars in Ophthalmology 2024; 0: 1-3
121394 MicroPulse Transscleral Laser Therapy: A Retrospective Study of Dose Efficacy and Safety
Nguyen J
Journal of Current Glaucoma Practice 2024; 18: 121-129
121059 A national analysis of systemic adverse events of beta-blockers used for glaucoma therapy
Aftab OM
Cutaneous and Ocular Toxicology 2024; 43: 293-298
121077 Uveal Effusion Syndrome Temporally Associated with Primary COVID-19 Infection
Oydanich M
Seminars in Ophthalmology 2024; 0: 1-3
121394 MicroPulse Transscleral Laser Therapy: A Retrospective Study of Dose Efficacy and Safety
González-Martínez OG
Journal of Current Glaucoma Practice 2024; 18: 121-129
119249 Pupillary Peaking & Presence of Dysphotopsias Following Glaucoma Tube Shunt Surgery
Oydanich M
Seminars in Ophthalmology 2024; 0: 1-6
122819 Are Alpha-2 Adrenergic Agonists Being Used in Infants?
Khan H
Journal of Ocular Pharmacology and Therapeutics 2024; 0:
120010 Adjunctive use of netarsudil 0.02% in the treatment of refractory glaucoma: a one year analysis
Yan J
International Ophthalmology 2024; 44: 335
121059 A national analysis of systemic adverse events of beta-blockers used for glaucoma therapy
Khan H
Cutaneous and Ocular Toxicology 2024; 43: 293-298
121077 Uveal Effusion Syndrome Temporally Associated with Primary COVID-19 Infection
Oydanich M
Seminars in Ophthalmology 2024; 0: 1-3
119249 Pupillary Peaking & Presence of Dysphotopsias Following Glaucoma Tube Shunt Surgery
Oydanich M
Seminars in Ophthalmology 2024; 0: 1-6
121059 A national analysis of systemic adverse events of beta-blockers used for glaucoma therapy
Sangani R
Cutaneous and Ocular Toxicology 2024; 43: 293-298
119249 Pupillary Peaking & Presence of Dysphotopsias Following Glaucoma Tube Shunt Surgery
Uppuluri S
Seminars in Ophthalmology 2024; 0: 1-6
120010 Adjunctive use of netarsudil 0.02% in the treatment of refractory glaucoma: a one year analysis
Bekerman VP; Bekerman VP
International Ophthalmology 2024; 44: 335
121077 Uveal Effusion Syndrome Temporally Associated with Primary COVID-19 Infection
Frohman L
Seminars in Ophthalmology 2024; 0: 1-3
121394 MicroPulse Transscleral Laser Therapy: A Retrospective Study of Dose Efficacy and Safety
Khouri AS
Journal of Current Glaucoma Practice 2024; 18: 121-129
122819 Are Alpha-2 Adrenergic Agonists Being Used in Infants?
Bargoud A; Khouri AS
Journal of Ocular Pharmacology and Therapeutics 2024; 0:
121059 A national analysis of systemic adverse events of beta-blockers used for glaucoma therapy
Khouri AS
Cutaneous and Ocular Toxicology 2024; 43: 293-298
121077 Uveal Effusion Syndrome Temporally Associated with Primary COVID-19 Infection
Khouri AS
Seminars in Ophthalmology 2024; 0: 1-3
119249 Pupillary Peaking & Presence of Dysphotopsias Following Glaucoma Tube Shunt Surgery
Verma R
Seminars in Ophthalmology 2024; 0: 1-6
120010 Adjunctive use of netarsudil 0.02% in the treatment of refractory glaucoma: a one year analysis
Khouri AS
International Ophthalmology 2024; 44: 335
119249 Pupillary Peaking & Presence of Dysphotopsias Following Glaucoma Tube Shunt Surgery
Khouri AS
Seminars in Ophthalmology 2024; 0: 1-6
